ArticleAnnals of gastroenterological surgery2026
Enhancing Surgical Efficiency and Cost-Effectiveness With TaTME-Combined Robot-Assisted Surgery for Lower Rectal Cancer.
Article in Annals of gastroenterological surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Robot-assisted rectal surgery (RAS) offers improved dexterity and visualization; however, the high cost of equipment and consumables remains a major challenge for hospital management. At our institution, we have adopted a combined approach using transanal total mesorectal excision (TaTME) for lower rectal cancers, aiming to shorten operative time and enable two procedures per day to improve cost-efficiency. Methods: This retrospective cohort study included 112 patients who underwent RAS for rectal cancer between 2019 and 2024, excluding those requiring lateral lymph node dissection. Patients were divided into a robotic-only group (Ra/RS tumors, Results: Despite much lower tumor height from the anal verge (3 vs. 10 cm, Conclusions: TaTME-combined RAS for lower rectal cancer enables efficient surgical scheduling and improved cost-effectiveness while maintaining oncological safety. This strategy holds promise as a model for economically sustainable rectal cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.